<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

3 min read

Navigating Choppy Waters: Q422 Neuromodulation Market Recap

3/20/23 10:06 AM

Q422 Nueromodulation HEADER v3While the macro environment is improving, some neuromodulation companies and segments navigated choppy waters in Q422

While the macro environment continued to improve in Q422, the waters remain choppy for some neuromodulation companies and segments. Competitors are making gains on new and differentiated product offerings, strengthening demand and expanding indications. These gains are offset by the residual effects of the pandemic, reimbursement challenges, stubborn inflationary pressures and currency exchange headwinds." For FY22, the spinal cord stimulation (SCS) segment showed signs of recovery by year-end while deep brain stimulation (DBS) slowed on replacement headwinds for some companies.
 
Among the many topics covered in detail in our comprehensive Q422 Neuromodulation Market Recap* article:
  • Complete Q422 Neuromodulation Market Overview
  • SmartTRAK's Expert Market Analysis and Insights
  • All Company News, Revenues, Data, Charts and Shares
  • Spinal Cord Stimulation Sees Growth Exiting 2022
  • Macro Environment Improving
  • Innovation, Expanding Indications Driving Growth
  • Potential Payer Headwinds
  • DBS Slows on Replacement Headwinds, Share Shifts
  • Q422 Clinical/Regulatory Highlights
For FY22, the spinal cord stimulation (SCS) segment showed signs of recovery by year-end while deep brain stimulation (DBS) slowed on replacement headwinds for some companies. Lingering effects of the pandemic also continue to impact the market including hospital staffing constraints, as well as supply chain disruptions, currency fluctuations and ...
*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.
Learn More about Subscribing to SmartTRAK

SmartTRAK
is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.
Anne Staylor
Written by Anne Staylor

Former Senior Editor, Medtech Insight. +25 years in various leadership roles in business intelligence, marketing, communications, product management, and consulting for medical device industry, hospitals, physician groups, insurers. Registered nurse and former Director of Marketing for a national ambulatory surgery company.

  • There are no suggestions because the search field is empty.

Follow Us on Social Media

Recent Articles